IntegraGen is conducting groundbreaking research in the area of oncology biomarkers and the development of an advanced scientific software program that will aid in the interpretation of genome sequencing data obtained from cancer patients. Click here for the latest updates on our progress.

IntegraGen’s licensing partner GoPath Labs announces new CPT Code for reimbursement of miR-31-3p test in the U.S.

GoPath Laboratories, IntegraGen’s North American licensing partner for the company’s miR-31-3p test, announced that the American Medical Association (AMA) has assigned a new, discreet CPT (Current Procedural Technology) code to facilitate reimbursement of miR-31now®, a proprietary miRNA-based molecular test which predicts the potential clinical benefits associated with (…)  » 

IntegraGen Announces Publication of miR-31-3p Data in Clinical Cancer Research

IntegraGen announces the publication of the results of a definitive study reporting on the analysis of the expression of miR-31-3p in tumors from 370 RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial (AIO KRK-0306). The paper, entitled “Validation of miR-31-3p Expression Level to Predict (…)  » 

Technical Validation Data for miR-31-3p test Published in Biomarker Insights

IntegraGen is pleased to announce that a comprehensive summary of the results of validation studies associated with the company’s proprietary miR-31-3p expression test has been published online in Biomarker Insights following peer-review.

The paper entitled “Technical validation of a reverse-transcription quantitative polymerase chain reaction in vitro (…)  » 

IntegraGen announces miR-31-3p publication in Oncotarget

IntegraGen announces that results from an analysis of miR-31-3p expression in tumor samples from patients enrolled in the NEW EPOC clinical trial have been published online in Oncotarget. The paper entitled “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a (…)  »